Senores Pharmaceuticals (NSE:SENORES) Shares Outstanding (EOP): 46 Mil (As of Mar. 2026)


NSE:SENORES Senores Pharmaceuticals Ltd NSE:SENORES
18 GF Score
Price ₹1,409.80
! 7 Warning Signs
View Full Analysis

What is Senores Pharmaceuticals Shares Outstanding (EOP)?

Senores Pharmaceuticals NSE:SENORES +3.75% 18 Shares Outstanding (EOP) is 46 Mil as of Mar. 2026. GuruFocus rates NSE:SENORES with a GF Score™ of 18/100. The stock has 7 warning signs investors should review.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Senores Pharmaceuticals's shares outstanding for the quarter that ended in Mar. 2026 was 46 Mil.

Senores Pharmaceuticals's quarterly shares outstanding stayed the same from Dec. 2025 (46 Mil) to Mar. 2026 (46 Mil).

Senores Pharmaceuticals's annual shares outstanding stayed the same from Mar. 2025 (46 Mil) to Mar. 2026 (46 Mil).


Senores Pharmaceuticals  (NSE:SENORES) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Senores Pharmaceuticals Shares Outstanding (EOP) Related Terms


Senores Pharmaceuticals Shares Outstanding (EOP) Historical Data

* Premium members only.

The historical data trend for Senores Pharmaceuticals's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Senores Pharmaceuticals Shares Outstanding (EOP) Chart

Senores Pharmaceuticals Annual Data
Trend Mar22 Mar23 Mar24 Mar25 Mar26
Shares Outstanding (EOP)
46.05 46.05 46.05 46.05 46.05

Senores Pharmaceuticals Quarterly Data
Mar22 Mar23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 46.05 46.05 46.05 46.05 46.05

NSE:SENORES vs LLY, JNJ, ABBV: Shares Outstanding (EOP) Comparison

For the Drug Manufacturers - General subindustry, Senores Pharmaceuticals's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Senores Pharmaceuticals Shares Outstanding (EOP) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Senores Pharmaceuticals's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Senores Pharmaceuticals's Shares Outstanding (EOP) falls into.


NSE:SENORES
18GF Score
Senores Pharmaceuticals Ltd NSE:SENORES
Shares Outstanding (EOP) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Senores Pharmaceuticals Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (EOP) of 46 Mil mean?
Senores Pharmaceuticals (NSE:SENORES) has a Shares Outstanding (EOP) of 46 Mil as of Mar. 2026. The total shares a company has outstanding, at period-end. View historical data on Senores Pharmaceuticals and its competitors.
Is Senores Pharmaceuticals' Shares Outstanding (EOP) too high?
Senores Pharmaceuticals' current Shares Outstanding (EOP) is 46 Mil. Overall, Senores Pharmaceuticals has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Senores Pharmaceuticals' Shares Outstanding (EOP) compare to LLY and JNJ?
Senores Pharmaceuticals' Shares Outstanding (EOP) of 46 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Drug Manufacturers company?
A good Shares Outstanding (EOP) depends on the Drug Manufacturers industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on Senores Pharmaceuticals and its competitors. Senores Pharmaceuticals's current Shares Outstanding (EOP) is 46 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Senores Pharmaceuticals stock overvalued right now?
Senores Pharmaceuticals (NSE:SENORES) has a current Shares Outstanding (EOP) of 46 Mil. The current Shares Outstanding (EOP) is 46 Mil. Senores Pharmaceuticals' overall GF Score™ is 18/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For Senores Pharmaceuticals (NSE:SENORES), the current Shares Outstanding (EOP) is 46 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Senores Pharmaceuticals Business Description

Other Exchanges 544319:India
Address Ambali Bopal Road, 1101 to 1103, 11th floor, South Tower, ONE 42, Opposite Jayantilal Park, Ahmedabad, GJ, IND, 380054
Senores Pharmaceuticals Ltd is a research-driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for the Regulated Markets of the USA, Canada and United Kingdom across various therapeutic areas and dosage forms, with a presence in Emerging Markets. Its strength lies in identifying, developing and manufacturing a diverse range of specialty, underpenetrated and complex pharmaceutical products establishing the company as a preferred partner to certain customers. Through data analytics, research, market assessment and experienced management, It strategically identifies commercially underpenetrated molecules to launch products in the Regulated and Emerging Markets.
18GF Score

Get the complete analysis for NSE:SENORES

Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,409.80
Price